Trends of Mortality in End-Stage Liver Disease—China,2008–2020

作     者：Xiaoxiao Wang Huixin Liu Jinlei Qi Fangfang Zeng Lijun Wang Peng Yin Feng Liu Hongbo Li Yunning Liu Jiangmei Liu Lai Wei Xiaofeng Liang Yu Wang Huiying Rao Maigeng Zhou 

作者机构：Peking University People’s HospitalPeking University Hepatology InstituteBeijingChina Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver DiseasesBeijing International Cooperation Base for Science and Technology on NAFLD DiagnosisBeijingChina Peking University People’s HospitalDepartment of Clinical Epidemiology and BiostatisticsBeijingChina National Center for Chronic and Non-communicable Disease Control and PreventionChinese Center for Disease Control and PreventionBeijingChina Department of Public Health and Preventive MedicineSchool of MedicineJinan UniversityGuangzhou CityGuangdong ProvinceChina Disease Control and Prevention Institute of Jinan UniversityGuangzhou CityGuangdong ProvinceChina Jinan University-BioKangtai Vaccine InstituteJinan UniversityGuangzhou CityGuangdong ProvinceChina China Center for Economic ResearchNational School of DevelopmentPeking UniversityBeijingChina Beijing Tsinghua Changgung HospitalTsinghua UniversityBeijingChina Chinese Foundation for Hepatitis Prevention and ControlBeijingChina. 

出 版 物：《China CDC weekly》 (中国疾病预防控制中心周报（英文）)

年 卷 期：2023年第5卷第30期

页      面：657-663,I0001-I0009页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by the Beijing Natural Science Foundation[No.7232195] National Natural Science Foundation of China[No.81870406,and No.81602939] Capital’s Funds for Health Improvement and Research[No.2020-4-4087] Peking University Medicine Sailing Program for Young Scholars’Scientific&Technological Innovation[No.BMU2023YFJHPY025] Chinese foundation for hepatitis prevention and control-TianQing liver disease research fund subject[No.TQGB20210139] 

主　　题：prevention stratified burden 

摘      要：Introduction:Liver cancer and cirrhosis represent the most prevalent forms of end-stage liver diseases(ESLDs).Notably,in China,deaths attributed to ESLDs contribute significantly to the global mortality rate of these *** comprehension of the mortality profile associated with ESLDs in China could provide crucial insights into intervention prioritization,which could in turn help reduce the overall global burden of these ***:Data were obtained from China’s Disease Surveillance Points *** presentation includes both crude and age-standardized mortality rates,stratified by sex,residential location,and *** Joinpoint Regression,trends in annual mortality rates were estimated from the period of 2008 to 2020 and expressed as the average annual percentage change(AAPC).Results:In 2020,the gross mortality rate of ESLD stood at 30.08 cases per 100,000 individuals.A higher age-standardized ESLD mortality rate was observed in males and rural populations in comparison to their female and urban counterparts,***,the highest mortality rates associated with liver cancer and cirrhosis were reported in South and Southwest China,respectively.A positive correlation was noticed between age-specific ESLD mortality rates and advancing ***,an annual decrease in the ESLD mortality rate was observed from 2008 to *** urban contexts,the AAPC of cirrhosis was noted to be higher than that of liver ***:The mortality rate associated with ESLDs in China decreased between 2008 and ***,the death burden attributable to ESLD continues to be alarmingly *** initiatives should prioritize the reduction of ESLD mortality in particular populations:males,elderly individuals,and those residing in rural regions of South and Southwest *** emphasis of future interventions should beplaced on antiviral therapy for adults diagnosed with viral hepatitis,and on the prevention of hepatitis B virus(HBV